Vaxcyte, Inc. (PCVX) Down 4.5% — Time to Swap This for Something Better?
Vaxcyte, Inc. (PCVX) is under pressure this Thursday, last changing hands at $65.51 on the NASDAQ. That is a $3.11 decline from the prior close of $68.62. The drop leaves the stock about 27.8% below its 52-week high of $90.75, reached on October 5, 2026, so roughly a quarter of its value has come off in just over five weeks. The stock still sits about 54.5% above the bottom of its 52-week range of $42.40, but the recent direction has been plainly lower.
Turnover is light so far, with about 60,502 shares traded against a 90-day average of roughly 1.83 million. At this point in the session, the decline is coming on thin participation rather than a broad rush for the exits.
Why Vaxcyte, Inc. Price is Moving Lower
The weight on Vaxcyte comes from the cost of building out VAX-31 and the dilution used to pay for it. On October 9, the company closed offerings that raised about $1.1 billion net. The package included 8.58 million common shares sold at $64 and $575 million of convertible notes. The capital extends the runway, but it also added shares immediately and created a convertible overhang that could add more. The timing is hard to ignore. The stock peaked at $90.75 just four days before the offering closed and is now trading only modestly above the $64 issue price. Today's decline also gives back the 3.41% gain PCVX posted in the prior session, a day when the Biotech ETF (XBI) rose 0.81%. That points to stock-specific pressure rather than a lasting sector bid.
Q3 results, released on November 4, showed losses widening. EPS of -$1.99 beat the -$2.11 analysts expected but was worse than the -$1.56 posted a year earlier. Net loss rose to $297.1 million from $212.8 million. Spending is climbing as VAX-31 moves through late-stage development, and that is consistent with a trailing EPS of -$8.07 and a forward P/E of -8.51.
The clinical data was encouraging, but it came with a qualification. VAX-31 met the primary endpoints of the OPUS-1 study in 4,047 adults. However, two serotypes missed the company's prespecified noninferiority threshold against PCV21, though they met a historical threshold. Investors may weigh that nuance against a long road to approval. OPUS-2 and OPUS-3 results are not expected until the first half of 2027, and a BLA submission is targeted for the first half of 2028. Other vaccine makers offer little support today. Moderna, Inc. (MRNA, D-) is down 4.43%, and Revolution Medicines, Inc. (RVMD, D-) is off 1.77%. The near-term story for Vaxcyte remains one of heavy spending, dilution, and execution risk.
What is the Vaxcyte, Inc. Rating - Should I Sell?
Weiss Ratings assigns PCVX a D- rating. The rating was upgraded on 10/1/2025. Current recommendation is Sell. Even after that upgrade, the rating remains in Sell territory, which fits a clinical-stage company whose valuation rests on approvals still years away.
The strongest part of the profile is the balance sheet. Vaxcyte is rated Excellent on the Solvency Index. The roughly $1.1 billion raised in October gives a pre-commercial company with a $10.86 billion market cap the resources to fund OPUS-2, OPUS-3, and the work leading to a 2028 BLA without immediate financing strain. The Fair rating on the Total Return Index makes a similar point from the market's side. Despite the recent slide, the stock remains about 54.5% above its 52-week low of $42.40, so holders over the full measurement period have still seen meaningful gains. That rating is not higher because much of the advance has unwound since the October 5 peak.
The rest of the picture explains the D-. The Very Weak rating on the Growth Index reflects a business with no commercial product and losses moving the wrong way. Net loss rose about 40% year over year, to $297.1 million in the third quarter. The Very Weak Efficiency Index follows from the same fact. A trailing EPS of -$8.07 shows how much capital the VAX-31 program consumes before any return appears, and the company had to fund that burn by issuing equity and converts. Volatility is rated Weak. A 52-week range stretching from $42.40 to $90.75 and today's reversal from a 3.41% gain show how sharply the stock reprices on financing and trial news.
Within the Health Care sector, Vaxcyte sits alongside Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-). It trails IQVIA Holdings Inc. (IQV, D+) and Zoetis Inc. (ZTS, D+), whose established revenue bases support slightly better risk/reward profiles in Weiss's framework.
About Vaxcyte, Inc.
Vaxcyte, Inc. (PCVX) is a clinical-stage vaccine developer that designs conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company was incorporated in 2013 as SutroVax, Inc. and adopted the Vaxcyte name in May 2020. It is headquartered in San Carlos, California.
The pipeline centers on pneumococcal disease, one of the largest categories in the vaccine market. VAX-24 is a 24-valent, carrier-sparing pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease in infants. VAX-31 extends coverage to 31 serotypes and is being developed for both adults and children. VAX-XL is a third-generation pneumococcal conjugate candidate meant to extend that franchise further. Beyond pneumococcus, Vaxcyte is developing VAX-A1, a conjugate vaccine candidate targeting Group A Streptococcus. It is also developing VAX-PG, a protein vaccine candidate aimed at the keystone pathogen behind periodontitis, and VAX-GI, a preclinical candidate for dysentery and shigellosis caused by Shigella bacteria.
Vaxcyte's competitive pitch rests on its carrier-sparing design. The approach is intended to let the company pack more serotypes into a single vaccine than existing products, offering broader protection against a disease where coverage breadth is a key selling point. That positions VAX-31 as a direct challenger to entrenched pneumococcal vaccines such as PCV21. Success will still depend on regulators accepting its immune-response data, and on the company scaling manufacturing for a high-volume market.
Investor Outlook
Vaxcyte, Inc. (PCVX) carries a Weiss Rating of D- (Sell). With losses widening, fresh dilution on the books, and approval not targeted until after a 2028 BLA submission, caution is warranted. Investors should watch the OPUS-2 and OPUS-3 readouts expected in the first half of 2027, especially how the two serotypes that missed the prespecified threshold are treated, along with the quarterly pace of cash burn against the October capital raise. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--